SOPHiA GENETICS and Myriad Collaborate to Enhance Prostate Cancer Diagnostics
In an exciting new development, SOPHiA GENETICS and Myriad Genetics, Inc. have announced a strategic collaboration aimed at advancing novel technology for assessing genomic instability specifically related to prostate cancer. This partnership will not only enhance the precision of oncology approaches but also expand the accessibility of groundbreaking therapies to patients globally.
On October 8, 2026, both companies unveiled their commitment to advance the Prostate Genomic Instability Score (PrGIS) technology, a crucial biomarker designed to evaluate chromosomal instability linked to homologous recombination deficiency (HRD) in prostate cancer cases. As HRD emerges as a significant prognostic and predictive marker within the sphere of prostate cancer treatment, the collaboration seeks to enhance PrGIS application in clinical trials, thereby facilitating the introduction of companion diagnostic solutions to further personalize cancer care.
Myriad has developed PrGIS as an actionable biomarker, harnessing its proprietary MyChoice® CDx test, which is currently recognized in ovarian cancer diagnostics. The test will be adapted to produce the PrGIS score specifically for prostate cancer, marking a new frontier in its application and potentially revolutionizing treatment strategies for male patients.
Lou Welebob, Senior Vice President of Companion Diagnostics at Myriad Genetics, stated, "This collaboration showcases Myriad's biopharma capabilities to support the development of precision oncology treatments." Enhancing patient stratification in clinical trials is paramount, and the PrGIS technology is designed to assist biopharma partners in achieving this objective while speeding up the development and deployment of effective companion diagnostics for precision oncology.
SOPHiA GENETICS is on the forefront of innovation with its cloud-based and technology-agnostic platform, which aims to transform the way solid tumor diagnostics are approached. The company plans to develop a decentralized companion diagnostic solution incorporating Myriad's PrGIS technology, allowing for more extensive global access. Their platform connects over 1,000 institutions across more than 75 countries, and they are determined to make pivotal advancements in prostate cancer care.
Addressing the challenges of precision medicine accessibility, Jess Lambe, VP Managing Director of BioPharma Business Development at SOPHiA GENETICS, remarked, "Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world." This partnership aims to counteract that trend by combining Myriad's superior biomarker innovation with SOPHiA GENETICS' vast network to ensure innovative therapies are available to those who need them most.
Further amplifying the collaboration’s impact, Myriad Genetics is set to present research on PrGIS, co-authored with AstraZeneca, during the upcoming European Society for Medical Oncology (ESMO) Congress 2026. This research is expected to provide additional insights into the biomarker's relevance and validation, coming as a boost to the collaboration's aims.
SOPHiA GENETICS, listed on Nasdaq as SOPH, is a trailblazer in AI-native healthcare technology, positioned to revolutionize patient care and access to data-driven medicine worldwide. With their innovative SOPHiA DDM™ platform, they analyze complex genomic and multimodal data to provide real-time insights that enhance medical decisions on a global scale.
Myriad Genetics, recognized as a leader in molecular diagnostics, focuses on advancing health by providing critical genetic insights to guide treatment choices. Their commitment to improving patient care extends across various medical fields, and their partnership with SOPHiA GENETICS is poised to widen the horizon for prostate cancer diagnostics and beyond.
With the combined expertise of SOPHiA GENETICS and Myriad, this collaboration not only underlines the significance of innovation in healthcare but also represents a significant leap towards more personalized and effective cancer treatment strategies. As clinical developments unfold, the impact of this partnership promises to reshape how prostate cancer is diagnosed, treated, and managed, ultimately leading to improved outcomes for patients globally.
On October 8, 2026, both companies unveiled their commitment to advance the Prostate Genomic Instability Score (PrGIS) technology, a crucial biomarker designed to evaluate chromosomal instability linked to homologous recombination deficiency (HRD) in prostate cancer cases. As HRD emerges as a significant prognostic and predictive marker within the sphere of prostate cancer treatment, the collaboration seeks to enhance PrGIS application in clinical trials, thereby facilitating the introduction of companion diagnostic solutions to further personalize cancer care.
Myriad has developed PrGIS as an actionable biomarker, harnessing its proprietary MyChoice® CDx test, which is currently recognized in ovarian cancer diagnostics. The test will be adapted to produce the PrGIS score specifically for prostate cancer, marking a new frontier in its application and potentially revolutionizing treatment strategies for male patients.
Lou Welebob, Senior Vice President of Companion Diagnostics at Myriad Genetics, stated, "This collaboration showcases Myriad's biopharma capabilities to support the development of precision oncology treatments." Enhancing patient stratification in clinical trials is paramount, and the PrGIS technology is designed to assist biopharma partners in achieving this objective while speeding up the development and deployment of effective companion diagnostics for precision oncology.
SOPHiA GENETICS is on the forefront of innovation with its cloud-based and technology-agnostic platform, which aims to transform the way solid tumor diagnostics are approached. The company plans to develop a decentralized companion diagnostic solution incorporating Myriad's PrGIS technology, allowing for more extensive global access. Their platform connects over 1,000 institutions across more than 75 countries, and they are determined to make pivotal advancements in prostate cancer care.
Addressing the challenges of precision medicine accessibility, Jess Lambe, VP Managing Director of BioPharma Business Development at SOPHiA GENETICS, remarked, "Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world." This partnership aims to counteract that trend by combining Myriad's superior biomarker innovation with SOPHiA GENETICS' vast network to ensure innovative therapies are available to those who need them most.
Further amplifying the collaboration’s impact, Myriad Genetics is set to present research on PrGIS, co-authored with AstraZeneca, during the upcoming European Society for Medical Oncology (ESMO) Congress 2026. This research is expected to provide additional insights into the biomarker's relevance and validation, coming as a boost to the collaboration's aims.
SOPHiA GENETICS, listed on Nasdaq as SOPH, is a trailblazer in AI-native healthcare technology, positioned to revolutionize patient care and access to data-driven medicine worldwide. With their innovative SOPHiA DDM™ platform, they analyze complex genomic and multimodal data to provide real-time insights that enhance medical decisions on a global scale.
Myriad Genetics, recognized as a leader in molecular diagnostics, focuses on advancing health by providing critical genetic insights to guide treatment choices. Their commitment to improving patient care extends across various medical fields, and their partnership with SOPHiA GENETICS is poised to widen the horizon for prostate cancer diagnostics and beyond.
With the combined expertise of SOPHiA GENETICS and Myriad, this collaboration not only underlines the significance of innovation in healthcare but also represents a significant leap towards more personalized and effective cancer treatment strategies. As clinical developments unfold, the impact of this partnership promises to reshape how prostate cancer is diagnosed, treated, and managed, ultimately leading to improved outcomes for patients globally.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.